上尿路尿路上皮癌对非肌层浸润性膀胱癌BCG治疗反应的影响
该单中心回顾性研究纳入541例接受足量膀胱内BCG治疗的非肌层浸润性膀胱癌患者,其中59例(10.9%)合并上尿路尿路上皮癌。研究发现,BCG治疗前已诊断上尿路尿路上皮癌的患者,其膀胱癌复发率和进展率几乎翻倍,尤其高级别上尿路尿路上皮癌与更高的复发风险相关。
要点
- BCG治疗前有UTUC病史者复发率55.9% vs 34.0%,进展率更高
- UTUC-P组原位癌无乳头状瘤比例更高(20.6% vs 5.0%)
- 高级别UTUC-P较低级别复发风险更高(68.2% vs 25.0%)
核心结论
- NMIBC诊断前存在UTUC与足量BCG治疗后复发和进展率几乎翻倍相关。
研究设计与样本
- 单中心IRB批准的回顾性综述,纳入2000-2018年接受足量膀胱内BCG治疗的541例NMIBC患者。
主要发现
- 541例中59例(10.9%)诊断UTUC,其中34例NMIBC前有UTUC病史(UTUC-P,中位间隔13.1个月),25例NMIBC后发生UTUC(6例同时,19例异时,中位间隔12.1个月)。
- UTUC-P组较非UTUC组更常见膀胱Tis无乳头状瘤(20.6% vs 5.0%,P<0.001),但初次TURBT时T1期较少(8.8% vs 49.4%,P<0.001)。
- UTUC-P组复发更多(55.9% vs 34.0%,P=0.010),任何分期/分级进展更多(23.5% vs 9.8%,P=0.012),进展至肌层浸润或转移更多(17.6% vs 6.4%,P=0.014)。
- 高级别UTUC-P较低级别UTUC-P与NMIBC复发增加相关(68.2% vs 25.0%,P=0.049)。
- UTUC与膀胱肿瘤的时间关系对复发或进展率无显著差异,但该分析受样本量小限制。
临床怎么用
- 对计划接受BCG治疗的NMIBC患者,应评估有无UTUC病史以辅助风险分层和咨询。
- 有UTUC病史的NMIBC患者BCG治疗后需更密切随访复发和进展。
局限性
- 回顾性单中心设计。
- UTUC时间分析受样本量小限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin (BCG) response and progression in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We performed an institutional review board-approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US Food and Drug Administration, at our institution between 2000 and 2018. Patients were stratified by presence of any UTUC and time of UTUC diagnosis (preceding vs synchronous to NMIBC diagnosis or metachronous disease after NMIBC diagnosis). Descriptive statistics were used to summarize the data overall and by groups, and t-tests or Wilcoxon's rank sum tests and Pearson's chi-squared or Fisher's exact tests were used to analyse continuous and categorical data, respectively. RESULTS: Of 541 patients with NMIBC treated with adequate BCG, 59 (10.9 %) were diagnosed with UTUC. Of these, 34 had a history of UTUC prior to NMIBC (UTUC-P; median [interquartile range {IQR}] 13.1 [7.4-27.6] months prior), while 25 developed UTUC after diagnosis of NMIBC (six synchronous and 19 metachronous; median [IQR] 12.1 [1.7-28.1] months after). Compared to the non-UTUC group, patients with UTUC-P were more likely to exhibit Tis without papillary tumour in the bladder (20.6% vs 5.0%; P < 0.001), but were less likely to have T1 disease on index transurethral resection (8.8% vs 49.4%; P < 0.001). Patients with UTUC-P developed more recurrences (55.9% vs 34.0%; P = 0.010), any stage/grade progression (23.5% vs 9.8%; P = 0.012) and progression to muscle-invasive or metastatic disease (17.6% vs 6.4%; P = 0.014). The presence of high-grade UTUC-P compared to low-grade UTUC-P was associated with increased NMIBC recurrence (68.2% vs 25.0%; P = 0.049). There was no significant difference in rates of recurrence or progression based on timing of UTUC with respect to the index bladder tumour, although this analysis was limited by small numbers. CONCLUSIONS: Presence of UTUC prior to a diagnosis of NMIBC was associated with an almost twofold increased recurrence and progression rates after adequate BCG therapy. This should be considered when counselling patients and designing cohorts for clinical trials.
引用
- Bree KK, Hensley PJ, Brooks NA, et al. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021. PMID: 33484074. doi:10.1111/bju.15344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。